All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial is to find out the best dose and side effects of all-trans retinoic acid
(ATRA) and atezolizumab in treating patients with non-small cell lung cancer that has come
back (recurrent) or has spread to other places in the body (metastatic). All-trans retinoic
acid (ATRA) is made in the body from vitamin A and helps cells to grow and develop.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving all-trans retinoic acid (ATRA) and atezolizumab may help treat patients with
non-small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Dwight Owen
Treatments:
Antibodies, Monoclonal Atezolizumab Retinol palmitate Tretinoin Vitamin A Vitamins